S&P 500
744.39
-0.31%
DOW
517.08
+0.30%
NASDAQ
737.95
-0.36%
Russell
298.18
+0.88%
VIX
25.86
-0.54%
FTSE
45.69
+0.51%
Nikkei
96.97
+0.74%
BTC
62,183.99
-4.55%
ETH
1,652.70
-6.33%
Gold
384.59
-0.65%
Oil
112.69
-1.90%
Silver
58.91
-1.01%
S&P 500
744.39
-0.31%
DOW
517.08
+0.30%
NASDAQ
737.95
-0.36%
Russell
298.18
+0.88%
VIX
25.86
-0.54%
FTSE
45.69
+0.51%
Nikkei
96.97
+0.74%
BTC
62,183.99
-4.55%
ETH
1,652.70
-6.33%
Gold
384.59
-0.65%
Oil
112.69
-1.90%
Silver
58.91
-1.01%
Stock
Ti
News
Markets
Stocks
Screener
Calendar
Watchlist
Loading...
Home
/
Stocks
/
MIRM
/
News
MIRM
NASDAQ · Biotechnology
Mirum Pharmaceuticals Inc
Mid-Cap Stocks
Biotech Stocks
Healthcare Stocks
$107.77
+0.64 (+0.60%)
☆ Watch
As of Jun 22, 9:52 PM ET ·
Overview
Earnings
Forecast
Financials
News
Peers
Technicals
MIRM News
1 articles
Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted
Mirum Pharmaceuticals announced volixibat met its primary endpoint in a Phase 2b trial for PSC, reducing itch scores. Shares rose 9%. The company plans a pre-NDA FDA meeting this summer and a U.S. filing in H2 2026.
Markets
May 4
↑